Valneva’s Lyme Disease Jab Program Gets Pfizer Cash Boost

Through Equity Subscription Agreement

Pfizer will invest in partner Valneva’s late-stage Lyme disease jab program, providing much-needed financial support to the French firm which has suffered COVID-19 vaccine sales setbacks.  

Pfizer's Support Gives Valneva A Cash Boost • Source: Shutterstock

Pfizer Inc. will inject $95m into Valneva SE to consolidate the firms’ existing Lyme disease partnership, boosting the French company after a recent spate of commercial setbacks regarding its COVID-19 program.

The investment made under the equity subscription agreement represents 8.1% of Valneva’s share capital at a price of €9.49 per...

More from Business

More from Scrip